Literature DB >> 10998734

Pathophysiology of opioid tolerance and clinical approach to the opioid-tolerant patient.

O de Leon-Casasola1, A Yarussi.   

Abstract

The physiologic basis for opioid tolerance has been elucidated, resulting in a better understanding of this problem. As a result of this ongoing effort, patients exhibiting opioid tolerance can now expect better pain management both in the postoperative period and during the course of their treatment. This article outlines the pathophysiology of opioid tolerance and a practical clinical approach to this problem.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10998734     DOI： 10.1007/s11916-000-0080-9

Source DB:  PubMed          Journal:  Curr Rev Pain        ISSN： 1069-5850


  19 in total

1.  Epidural sufentanil for acute pain control in a patient with extreme opioid dependency.

Authors:  O A de Leon-Casasola; M J Lema
Journal:  Anesthesiology       Date:  1992-05       Impact factor: 7.892

2.  Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.

Authors:  K A Trujillo; H Akil
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

3.  Continuous intrathecal administration of morphine via an osmotic minipump in the rat.

Authors:  Z Wiesenfeld; L L Gustafsson
Journal:  Brain Res       Date:  1982-09-09       Impact factor: 3.252

4.  CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration.

Authors:  William G Brose; Darrell L Tanelian; Jay B Brodsky; James B D Mark; Michael J Cousins
Journal:  Pain       Date:  1991-04       Impact factor: 6.961

5.  Morphine-induced opioid receptor down-regulation detected in intact adult rat brain cells.

Authors:  N F Rogers; E el-Fakahany
Journal:  Eur J Pharmacol       Date:  1986-05-27       Impact factor: 4.432

6.  The development of morphine tolerance and dependence is associated with translocation of protein kinase C.

Authors:  David J Mayer; Jianren Mao; Donald D Price
Journal:  Pain       Date:  1995-06       Impact factor: 6.961

7.  Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea.

Authors:  C Chavkin; A Goldstein
Journal:  Life Sci       Date:  1982 Oct 18-25       Impact factor: 5.037

8.  Epidural bupivacaine/sufentanil therapy for postoperative pain control in patients tolerant to opioid and unresponsive to epidural bupivacaine/morphine.

Authors:  O A de Leon-Casasola; M J Lema
Journal:  Anesthesiology       Date:  1994-02       Impact factor: 7.892

9.  The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids.

Authors:  Kathryn Elliott; Nobuko Minami; Yuri A Kolesnikov; Gavril W Pasternak; Charles E Inturrisi
Journal:  Pain       Date:  1994-01       Impact factor: 6.961

10.  A comparison of postoperative epidural analgesia between patients with chronic cancer taking high doses of oral opioids versus opioid-naive patients.

Authors:  O A de Leon-Casasola; D P Myers; S Donaparthi; D R Bacon; J Peppriell; J Rempel; M J Lema
Journal:  Anesth Analg       Date:  1993-02       Impact factor: 5.108
View more
  2 in total

Review 1.  Pain management mini-series. Part II. Chronic opioid drug therapy: implications for perioperative anesthesia and pain management.

Authors:  Robert B Fisher; Quinn L Johnson; Joseph L Reeves-Viets
Journal:  Mo Med       Date:  2013 May-Jun

2.  The Challenge of Converting "Failed Spinal Cord Stimulation Syndrome" Back to Clinical Success, Using SCS Reprogramming as Salvage Therapy, through Neurostimulation Adapters Combined with 3D-Computerized Pain Mapping Assessment: A Real Life Retrospective Study.

Authors:  Philippe Rigoard; Amine Ounajim; Lisa Goudman; Tania Banor; France Héroux; Manuel Roulaud; Etienne Babin; Bénédicte Bouche; Philippe Page; Bertille Lorgeoux; Sandrine Baron; Nihel Adjali; Kevin Nivole; Mathilde Many; Elodie Charrier; Delphine Rannou; Laure Poupin; Chantal Wood; Romain David; Maarten Moens; Maxime Billot
Journal:  J Clin Med       Date:  2022-01-05       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.